Table 5 Outcome data according to NPM1... | American Society of Hematology

Table 5

Outcome data according to NPM1 and FLT3/ITD mutant status in the total cohort of 1217 patients

	NPM1⁻, %	NPM1⁺, %	OR (CI)	P	NPM1⁻, ITD⁻, %	NPM1⁻, ITD⁺, %	NPM1⁺, ITD⁻, %	NPM1⁺, ITD⁺, %	OR (CI) for NPM1 stratified by ITD status	P	Het.
CR	78	91	0.40 (0.30-0.55)	<.001	78	77	94	87	0.38 (0.28-0.52)	<.001	0.3
RD	15	3	0.28 (0.19-0.41)	<.001	15	17	2	6	0.26 (0.18-0.38)	<.001	0.6
ID	7	6	0.86 (0.54-1.36)	.5	7	7	5	7	0.83 (0.52-1.34)	.4	0.4
OS at 5 yr	31	49	0.67 (0.58-0.77)	<.001	34	15	59	35	0.60 (0.52-0.69)	<.001	0.6
DFS at 5 yr	31	45	0.72 (0.62-0.84)	<.001	34	15	55	31	0.62 (0.53-0.73)	<.001	0.7
RR at 5 yr	61	46	0.69 (0.58-0.82)	<.001	57	79	34	63	0.57 (0.48-0.69)	<.001	0.6

	NPM1⁻, %	NPM1⁺, %	OR (CI)	P	NPM1⁻, ITD⁻, %	NPM1⁻, ITD⁺, %	NPM1⁺, ITD⁻, %	NPM1⁺, ITD⁺, %	OR (CI) for NPM1 stratified by ITD status	P	Het.
CR	78	91	0.40 (0.30-0.55)	<.001	78	77	94	87	0.38 (0.28-0.52)	<.001	0.3
RD	15	3	0.28 (0.19-0.41)	<.001	15	17	2	6	0.26 (0.18-0.38)	<.001	0.6
ID	7	6	0.86 (0.54-1.36)	.5	7	7	5	7	0.83 (0.52-1.34)	.4	0.4
OS at 5 yr	31	49	0.67 (0.58-0.77)	<.001	34	15	59	35	0.60 (0.52-0.69)	<.001	0.6
DFS at 5 yr	31	45	0.72 (0.62-0.84)	<.001	34	15	55	31	0.62 (0.53-0.73)	<.001	0.7
RR at 5 yr	61	46	0.69 (0.58-0.82)	<.001	57	79	34	63	0.57 (0.48-0.69)	<.001	0.6

Het. indicates testing for heterogeneity (P value for difference in effect of an NPM1 mutation in FLT3/ITD⁻ and ITD⁺ patients).